Best Bioverge Podcasts (2025)

1
Decoding Biotech: A Deep Dive into AI and Platform Technologies 49:02

Play Pause

1+ y ago49:02

49:02

Kiersten Stead, Co-Founder and Managing Partner of DCVC Bio sits down with Neil to discuss her firm’s approach to deep tech investing in biotech, her focus on platform technologies, and how to separate what’s real from what’s hype in AIBy The Bioverge Podcast

1
Financing Biotech: Portfolio Theory and Netflix-Inspired Models 1:05:11

2y ago1:05:11

1:05:11

Andrew Lo, Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management, sits down with Neil to discuss his application of portfolio theory to address the challenges of funding drug development and how a Netflix subscription model can address the coming crisis in funding high-priced curati…

1
Bringing A Hub-and-Spoke Business Model to Regenerative Medicine 44:31

2y ago44:31

44:31

Faizzan Ahmad, Co-Founder and CEO of Cure8bio, sits down with Neil to discuss its growing portfolio of regenerative medicines in development, its hub-and-spoke business model designed to leverage resources and reduce risk, and its push toward curative therapies.By The Bioverge Podcast

1
Enlisting Liquid Biopsies in the Fight Against Chronic Diseases 57:14

2y ago57:14

57:14

Nathan Hunkapiller, Chief Scientific Officer and Co-Founder of Curve Biosciences, sits down with Neil to discuss liquid biopsies, the company’s efforts to expand the use of these blood-based tests to improve the treatment of chronic diseases, and how it is enabling earlier intervention.By The Bioverge Podcast

1
Developing Targeted Therapies to Address Heart Failure 45:50

2y ago45:50

45:50

Drew Titmarsh, Co-Founder and CEO of Dynomics, sits down with Neil to discuss that lack of innovative therapies to treat heat disease, the company’s discovery platform that uses engineered cardiac organoids that function like adult human heart tissue, and how the company is using this to develop precision therapies to address the root causes of hea…

1
Speeding Drug Development by Unlocking the Mechanism of Action of Cancer Therapies 50:20

2y ago50:20

50:20

David Li, Co-Founder and CEO of Meliora Therapeutics, sits down with Neil to discuss why the mechanism of action for cancer therapies in development is poorly understood, how this leads to a high and costly clinical failure rate, and how Meliora's platform technology uncovers the true mechanism of action of a drug and it enables it to identify prom…

1
Enlisting the Viral Immune System in the Fight Against Cancer 39:47

2+ y ago39:47

39:47

Anat Burkovitz, CEO of TrojanBio, sits down with Neil to discuss its AI-drive antibodies platform, how it enlists the viral immune system in the fight against cancer, and why she thinks the technology will broaden the population of patients who will benefit from immunotherapies.By The Bioverge Podcast

1
Bringing Precision Medicine to Psychiatry 55:04

2+ y ago55:04

55:04

Amit Etkin, Founder and CEO of Alto Neuroscience, sits down with Neil to discuss the lack of innovation in psychiatric medicines, how the company has identified AI-derived brain biomarkers, and how that is fueling its pipeline of precision therapies to treat mental health disorders.By The Bioverge Podcast

1
Reengineering Healthcare and Medicine with Technology 51:51

2+ y ago51:51

51:51

Vineeta Agarwala, General Partner at Andreessen Horowitz's Bio + Health Fund, sits down with Neil to discuss their investment process, how technology is transforming biotech and healthcare, and why she thinks drug development is becoming more and more like software development.By The Bioverge Podcast

1
Unlocking the Potential of Genetic Medicines 57:44

2+ y ago57:44

57:44

David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.…

1
#9 - Investing in Forge Health, PsychHub, and XP Health, featuring Jon Gordon of HC9 Ventures 19:44

2+ y ago19:44

19:44

Joining as today's guest is Jon Gordon, Co-Founder & Managing General Partner at HC9 Ventures In this episode, Gordon discusses: His background An overview of HC9 Ventures The launch of their first fund 3 latest investments - Forge Health, PsychHub, and XP Health What's next? To learn more about HC9 Ventures please use the links below: - Website - …

1
Making Medcines Affordable for Everyone 1:04:58

2+ y ago1:04:58

1:04:58

Peter Kolchinsky, Founder and Managing Director of RA Capital Management and Founder of the nonprofit No Patient Left Behind, sits down with Neil to discuss his book “The Great American Drug Deal,” policy fights over pricing, and his organization’s efforts to make medicines affordable for all Americans.…

1
Unleashing the Power of Gene Therapy for a Broad Universe of Diseases 53:06

2+ y ago53:06

53:06

Kriya Therapeutics Co-Founder, Chairman, and CEO Shankar Ramaswamy sits down with Neil. He discusses how the company is changing the way gene therapies are designed, developed, and manufactured in an effort to cut costs, accelerate the time to market, and expand the reach of gene therapies to a broad universe of disease.…

1
A Bioinformatician Turned Investor Seeks to Transform Drug Development with Technology 1:04:48

2+ y ago1:04:48

1:04:48

Francisco Gimenez, a member of the 8VC investment team, sits down with Neil to discuss how his background in data science and bioinformatics shapes his investment approach and the potential to transform drug development with technology.By The Bioverge Podcast

1
A Rockstar Investor Who Backs Transformational Technologies 56:06

2+ y ago56:06

56:06

D.A. Wallach sits down with Neil to discuss his journey from recording artists to venture investors, his co-founding of Time BioVentures, and his vision from transforming biotechnology and healthcare with technology.By The Bioverge Podcast

1
Harnessing CRISPR to Cure Infectious Diseases 55:47

2+ y ago55:47

55:47

Daniel Dornbusch, CEO of Excision BioTherapeutics, sits down with Neil to discuss his company’s efforts to develop CRISPR-based therapies to cure HIV and other viral infectious diseases.By The Bioverge Podcast

1
Finding Purpose in Building Early-Stage Companies 51:27

2+ y ago51:27

51:27

Khosla Ventures Partner Gwen Cheni sits down with Neil to talk her migration from Wall Street to early-stage TechBio companies, how that has shaped her investment approach in start-ups, and what emerging technologies excite her today.By The Bioverge Podcast

1
Developing Next-Generation Small Molecule Drugs 49:36

2+ y ago49:36

49:36

Ramsey Homsany, co-founder and president of Octant Bio, sits down with Neil to discuss the company’s efforts to tackle complex diseases with next-generation small molecule drugs by harnessing synthetic biology to better understand the biochemical mechanisms of its targets, his unusual path to leadership of a biotechnology company, and Octant’s coll…

1
The Repurpose Driven Life 51:10

2+ y ago51:10

51:10

On this episode, David Fajgenbaum, co-founder of Every Cure, sits down with Neil to discuss his new nonprofit, which is seeking to unlock the potential of already approved drugs to treat diseases for which they have not been approved. Fajgenbuam, co-founder and executive director of the Castleman Disease Collaborative Network and assistant professo…

1
Using Food as Medicine to Extend Health and Treat Disease 56:48

3y ago56:48

56:48

Joseph Antoun, CEO of L-Nutra, sits down with Neil to discuss how his company is using state-of-the art science and randomized, placebo-controlled clinical studies to use diet to extend healthy lifespans and treat a wide range of diseases.By The Bioverge Podcast

1
Harnessing the Many Flavors of CRISPR to Detect and Cure Disease 56:08

3y ago56:08

56:08

Trevor Martin, co-founder of CEO of Mammoth Biosciences, sits down with Neil to discuss the power of CRISPR as a diagnostic and therapeutic tool, his company's efforts to discover new CRISPR enzymes, and how the company is building a therapeutic pipeline through partnerships and on its own.By The Bioverge Podcast

1
#8 - Investing in AmplifyMD, Arpeggio Biosciences, & CalmWave, featuring Amit Garg, Managing Partner at Tau Ventures 17:52

3y ago17:52

17:52

Joining as today's guest is Amit Garg, Managing Partner at Tau Ventures. In this episode, Garg discusses: AmplifyMD Arpeggio Biosciences CalmWave Recent Investments What Tau Ventures Does Why Tau Ventures invested in each of these companies What's next? To learn more about Tau Ventures please use the links below: - Website - LinkedIn This episode i…

1
Developing Next-Generation in Vivo Cell and Gene Therapies 1:07:03

3y ago1:07:03

1:07:03

David Johnson, founder and CEO of GigaMune, sits down with Neil to discuss his company's efforts to develop in vivo cell and gene therapies to treat cancer and autoimmune conditions.By The Bioverge Podcast

1
#7 - Investing in Enveda Biosciences, & Bionaut Labs, Ochre Bio (Bioverge) 15:28

3+ y ago15:28

15:28

Joining as today's guest is Neil Littman, CEO at Bioverge. In this episode, Littman discusses: His background A quick overview of Bioverge What he looks for in companies What's next? To learn more about Bioverge please use the links below: - Website - LinkedIn Also, be sure to follow us on our social channels: - Website - Facebook - LinkedIn - Twit…

1
Addressing the Challenges of Chronic Liver Disease 45:18

3+ y ago45:18

45:18

Jack O’Meara, co-founder and CEO of Ochre Bio, sits down with Neil to discuss the large unmet health need created by chronic liver disease and the company’s efforts to develop RNA therapies address it.By The Bioverge Podcast

1
#6 - Investing in Neucruit, Quantively, HiHealth (Nina Capital) 19:34

3+ y ago19:34

19:34

Joining as today's guest is Marta Gaia Zanchi, managing partner at Nina Capital. In this episode, Dr. Kumar discusses: Her background, A quick overview of Nina Capital 3 recent investments Why she invested in each To learn more about Nina Capital please use the links below: - Website - LinkedIn Also, be sure to follow us on our social channels: - W…

1
#5 - Investing in Medable, Alpha Medical, and Osso VR (GSR Ventures) 13:10

3+ y ago13:10

13:10

Joining as today's guest is Dr. Sunny Kumar, Partner at GSR Ventures. In this episode, Dr. Kumar discusses: His background The firm Recent investments: Medible, Alpha Medical, Osso VR What they do, why you invested? To learn more about GSR Ventures please use the links below: - Website - LinkedIn Also, be sure to follow us on our social channels: -…

1
Engineering Intelligence into Cell and Gene Therapies 51:29

3+ y ago51:29

51:29

Tim Lu, co-founder and CEO of Senti Bio, sits down with Neil to discuss how his company is using synthetic biology to engineer cell and gene therapies with programmable gene circuits to make therapies that are safer, more effective, and precise.By The Bioverge Podcast

1
Changing Drug Discovery with Transomics 45:54

3+ y ago45:54

45:54

On this episode, Neil sits down with Samantha Dale Strasser, co-founder and chief scientific officer of Pepper Bio, to discuss the company’s computational drug discovery platform and how its transomics approach can lead to the discovery and development of safer and more effective drugs.By The Bioverge Podcast

1
Accelerating Timelines and Improving Outcomes with a Predictive Precision Medicine Platform 55:32

3+ y ago55:32

55:32

Matt De Silva, founder and executive chairman of Notable Labs, sits down with Neil to discuss his company’s predictive precision medicine platform and its move to leverage its platform to develop its own precision cancer therapies.By The Bioverge Podcast

1
#4 - Themes in Healthcare To Watch (Inspired Capital) 16:01

3+ y ago16:01

16:01

Joining as today's guest is Charlotte Ross, Investor at Inspired Capital. "Inspired Capital is a $500M early-stage technology venture fund focused on supporting the next wave of exceptional entrepreneurs." In this episode, Charlotte discusses: Her background Overview of Inspired Capital Themes in healthcare they are exploring What she looks for whe…

1
#3 - Investing in Terapify & HouseRx (1984 Ventures) 11:13

3+ y ago11:13

11:13

Joining as today's guest is Dr. Farzad Soleimani, Healthcare Partner at 1984 Ventures. "1984 Ventures believes the next wave of value creation will come not from hype but rather from applying technology to large, established industries--industries like real estate, logistics, business back office and finance." In this episode, Dr. Soleimani discuss…

1
#2 - Investing in HeyRenee (Quiet Capital) 9:01

3+ y ago9:01

9:01

Joining as today's guest is Morgan Livermore, Partner at Quiet Capital. "Move the world further, faster, with Quiet Capital. Quiet Capital invests in technology businesses early to create long-term value." In this episode, Morgan discussed his recent healthcare investment: HeyRenee To learn more about Quiet Capital please use the links below: - Web…

1
#1 - Investing in Signos, Klivo, & Marigold Health (Tau Ventures) 14:52

3+ y ago14:52

14:52

Joining as today's guest is Amit Garg, Co-Founder & Managing Partner at Tau Ventures. "Tau Ventures is an AI-first, seed-first fund in digital health, automation (cars, drones, robots) & enterprise." In this episode, Amit discussed the following recent investments: Signos Klivo Marigold Health To learn more about Tau Ventures please use the links b…

1
A Wall Street Veteran Discusses Where Biotech Has Been and What's Ahead 1:07:26

3+ y ago1:07:26

1:07:26

Dennis Purcell, founder of Aisling Capital and former managing director of the Life Sciences Investment Banking Group at Chase H&Q, sits down with Neil discuss where biotech has been and what's ahead for the sector.By The Bioverge Podcast

1
Curing Blindness with Cell Therapy 50:34

3+ y ago50:34

50:34

On this episode, Arnaud Lacoste, chief scientific officer of Aurion Biotech, sits down with Neil Littman to discuss the company’s experimental cell therapy to restore vision in patients with corneal endothelial disease.By The Bioverge Podcast

1
From Bugs to Drugs 46:06

4y ago46:06

46:06

Kareem Barghouti, co-founder and CEO of VastBiome, sits down with Neil to discuss how his company is using AI to map the gut microbiome to discover novel therapies.By The Bioverge Podcast

1
Forging a TechBio Culture 46:37

4y ago46:37

46:37

This week Viswa Colluru, founder and CEO of Enveda Bio sits down with Neil to discuss AI in drug development, and the challenges of managing and forging a TechBio culture.By The Bioverge Podcast

1
Investing in the Bio-Based Future 42:31

4y ago42:31

42:31

Lindy Fishburne, managing partner of Breakout Ventures, sits down with Neil to discuss investing in seed- and early-stage bioscience companies, and what she learned working with entrepreneurial scientists at Breakout Labs.By The Bioverge Podcast

1
Evolving Failures in an Evolving Pandemic and What Needs to Be Done 55:36

4y ago55:36

55:36

Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.By The Bioverge Podcast

1
Bridging the Translational Science Divide 39:43

4y ago39:43

39:43

Pete Schultz, CEO of Scripps Research, sits down with Neil to discuss his efforts to create a self-sustaining nonprofit drug discovery and development institute and it’s work to advance small molecule regenerative therapies from the lab to the clinic.By The Bioverge Podcast

1
Why the FDA Was Right to Approve Biogen's Aduhelm 42:10

4y ago42:10

42:10

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.By The Bioverge Podcast

1
Democratizing Entrepreneurship 54:25

4y ago54:25

54:25

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discusses OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.By The Bioverge Podcast

1
Managing the Challenges of Scaling Cell and Gene Therapies 40:34

4y ago40:34

40:34

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.By The Bioverge Podcast

1
Advancing a Pipeline of Off-The-Shelf Cell Therapies 45:13

4+ y ago45:13

45:13

Brian Culley, CEO of Lineage Cell Therapeutics, sits down with Neil to discuss his company’s efforts to develop off-the-shelf cell therapies to treat degenerative retinal disease, spinal cord injury, and cancer.By The Bioverge Podcast

1
Weighing the Strengths and Weakness of Various COVID-19 Vaccines 55:30

4+ y ago55:30

55:30

Craig Laferrière head of vaccine development for Novateur Ventures, joins Neil to discuss the relative strengths and weaknesses of the different COVID-19 vaccines in use and in development.By The Bioverge Podcast

1
Improving Epilepsy Outcomes with Digital Health Technology 39:47

4+ y ago39:47

39:47

Rachel Kuperman, CEO of Eysz, sits down with Neil to discuss her company’s efforts to develop a digital health platform using passive eye-movements as input to measure, diagnose, and predict neurological disease starting with epilepsy.By The Bioverge Podcast

1
Removing Toxins from Cerebrospinal Fluid to Treat Neurodegenerative Diseases 32:00

4+ y ago32:00

32:00

Anthony DePasqua, CEO of EnClear Therapies, sits down with Neil to discuss the company’s technology in development to remove toxic proteins from cerebrospinal spinal fluid to treat patients with ALS and other neurodegenerative conditions.By The Bioverge Podcast

1
Decoding the World 56:32

4+ y ago56:32

56:32

Arvind Gupta, founder of IndieBio and co-lead of the engineering biology practice at the venture capital firm Mayfield, and Po Bronson, author and managing director and partner at IndieBio, sit down with Neil to discuss their new book Decoding the World, IndieBio, and the future of biotech.By The Bioverge Podcast

1
Making Long-Term Bets on Longevity 34:48

4+ y ago34:48

34:48

About ten years ago, futurist Sonia Arrison in her book “100 Plus” explored the coming age of longevity and the broad impacts it would have. Now, as a venture investor, she’s backing companies that are positively impacting longevity through her 100 Plus Capital. In this episode, Neil talks to Arrison about the area of longevity, her investment appr…